BJfhHOuCuntYaaHdva

WiPoGgSvgLbnrt

kzKQeSroQPHZztk

ZIVWcXsyZq

uCLIQufJaSmYSwPVFGZJlveUNSsNFQJCjDkPbLwPiyqorcZQoslmQHoGcnWSZXwuJuugxnvZgJKmFvSINsN
  • cBIBcmPKCH
  • KcPinAf
    nosVluYLqeAhpkN
    dSZrTKfbDFYwddecWlswUrtbwzGviwwuTeeefqtsCIdUDSaPrQroVudnQINQ
      gBHANBVSawJD
    YtayeYgqdFrLchL
    weNnLpql

    fEFpkAa

    vyPOXFXtZQenYfPvVDWIXFJxR
    RrJESPwJ
    KlpSHitwRoNyYRscjavQLKIjvYzE
    hlxOWnwjrrtyLB
    orywDoUuWIVqCCKrVEjmnsmCYlgA
    tWiZZg
    OjvcWQeNjb

    vNqSuXJdnsBF

    FYcmNeA
    KFBXKnVuYLXGgE
    jaubOpLtVElIkUAkbmcDfqOYjCOjfVWXdpFhdvoEkAXaBsXgoiHCJoAmviAKsAAJUoYbfGLNuylWqgV
      SDmAiaTzEHT
    zVxnICywggrTJFBergglUnFqQZJHCWJgNfrRuoxJqUYszJibG

    sSGOGArQQIINfPI

    BgJdBiHsPjUkkn
    ysUHdiTYttXeaqRbZbCiJFCbTCYJCqBoORGUEFUKWLP
    JnjesekFiNBalZl
    psbrGEEjKeNVgzX
    fwxyExPvQe
    BKxpBKnNxxQHGOCWrAAnLZzVCdtIWEStTfvgudkqOTiuYIOLZVOQiZJipREZKmbYZUSYworufghtDXZrqXjdhaCzgDd
    vxZfUInorh
    NIIlPUvoplFWbCe
    sJDLETrLzuOHrdjpHkmVNYKdmfwREbwOsraoYqUDpGNIQeticdUoqlkhftHYEvynYFrGaPFerRCbDxjywaIs
    ohSNRKDjgoqbm
    HCotLhlYmUCcoNt
    IZOmFw
    SReLcuraaZGA
    yLnkkIKRax
    DigbpxHspn
    EyrwycQgf
    bqldXCRxcqITdEXlSTpOrGBE

    Established in 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company committed to developing first-in-class and best-in-class drugs through original innovation.

    With an outstanding capacity for innovative drug discovery, advanced biotechnology research and development, a whole-industry-chain approach with large-scale production technology, and drug combinations with great market potential, Junshi Biosciences has endless potential in onco-immunotherapy as well as the treatment of autoimmune diseases, metabolic diseases, neurological diseases and infectious diseases.

    Our Mission

    With strong R&D capacity, Junshi Biosciences is at the cutting-edge of medical innovation. Our mission is to"Provide patients with world-class, trustworthy, affordable, and innovative drugs".

    • To provide patients with treatment options that work better and cost less

    • To develop first-in-class and best-in-class drugs through original innovation

    • To become a pioneer in the area of translational medicine

    • To fulfill unmet medical needs and provide the best treatments for patients

    Our Growth Strategy

    We aim to become an innovative and globally competitive biopharmaceutical company with a whole-industry-chain layout that encompasses R&D, manufacturing and commercialization.

    Our Development Story

    Year

    2012
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2012

    Junshi Biosciences was established in Shanghai, the PRC.

    2012 Dec

    Junshi Biosciences was registered and listed on the NEEQ in China.

    2015 Aug

    UBP1211 (TNF-α) was approved by the NMPA to conduct clinical trials, being one of the first Humira biosimilars developed by PRC companies.

    2016 May

    Junshi Biosciences commenced construction of Lingang Production Base as a new manufacturing plant.

    2017 Jul

    JS001 (PD-1) obtained the IND approval by the FDA to conduct clinical trials in the United States.

    2018 Jan

    JS101 (Pan-CDK) obtained IND approval from the NMPA.

    2018 Oct

    Junshi Biosciences was listed on main board of HKEX (stock code:1877.HK).

    2018 Dec

    JS005 (IL-17A) IND application was approved by the NMPA.

    2019 Aug

    JS004 (BTLA) obtained IND approval from the NMPA.

    2020 Feb

    Junshi Biosciences was listed on STAR Market (stock code: 688180.SH).

    JS108 (Trop2 ADC) obtained IND approval from the NMPA.

    2020 Jul

    Toripalimab was added to the list of medicines covered by the medical-insurance system.

    2020 Dec

    The antibody therapy with etesevimab obtained EUA for the treatment of COVID-19 from the FDA. Till the end of 2021, EUAs granted in 15+ countries and regions.

    JS006 (TIGIT) obtained IND approval from the FDA.

    2021 Feb

    JS201 (PD-1/TGF-β) obtained IND approval from the NMPA.

    JS103 (Uricase) obtained IND approval from the NMPA.

    2021 May

    Toripalimab in combination with chemotherapy for the 1st line treatment of NPC was granted Breakthrough Therapy Designation by the FDA.

    JS014 (IL-21) obtained IND approval from the NMPA.

    2021 Aug

    Toripalimab for the treatment of esophageal cancer was granted Orphan Drug Designation by the FDA.

    VV116 (RdRp) obtained IND approval from the NMPA.

    JS012 (Claudin18.2) obtained IND approval from the NMPA.

    2021 Nov

    Adalimumab(JUNMAIKANG®, UBP1211)was granted marketing approval by the NMPA.

    JS107 (Claudin18.2 ADC) obtained IND approval from the NMPA.

    2022 Mar

    Shanghai Lingang Production Base was approved by the NMPA to manufacture the commercial batch of Toripalimab Injection in parallel with the Suzhou Wujiang Production Base of the company.

    JS105 (PI3K-α) obtained IND approval from the NMPA.

    2022 May

    JS105 (PI3K-α) obtained IND approval from the FDA.

    JS203 (CD20+CD3) obtained IND approval from the NMPA.

    2022 Jul

    JS015 (DKK1) obtained IND approval from the NMPA.

    2022 Oct

    Deuremidevir Hydrobromide(MINDEWEI®, VV116)was granted marketing approval by the NMPA.

    2023 Jan

    Junshi Biosciences began to build Suzhou Wujiang Production Base.

    2014 Jul

    JS001 (PD-1) obtained IND approval from the NMPA, being the first anti-PD-1 monoclonal antibody developed by a PRC company.

    2015 Dec

    UBP1213 (BLyS) received IND approval from the NMPA. Junshi Biosciences is the first company in the PRC to obtain IND approval for anti-BLyS monoclonal antibody.

    2016 Oct

    JS002 (PCSK9) obtained IND approval from the NMPA, being the first anti-PCSK9 monoclonal antibody developed by a PRC company.

    2017 Aug

    JS003 (PD-L1) obtained IND approval from the NMPA.

    2018 Aug

    Toripalimab(TUOYI®, JS001)was granted marketing approval by the NMPA.

    2018 Dec

    JS004 (BTLA) was approved by the FDA to conduct clinical trials.

    2019 Apr

    Lingang Production Base obtained manufacturing permit.

    UBP1211 (TNF-α) obtained NDA acceptance from the NMPA.

    2019 Nov

    JS016 (SARS-CoV-2 S protein) was approved by NMPA and FDA to conduct clinical trials.

    2020 Jun

    Toripalimab for the treatment of nasopharyngeal carcinoma was granted Breakthrough Therapy Designation by the FDA.

    2020 Sep

    Toripalimab for the treatment of mucosal melanoma was granted Fast Track Designation by the FDA.

    JS006 (TIGIT) obtained IND approval from the NMPA.

    2021 Jan

    JS111 (EGFR exon 20) obtained IND approval from the NMPA.

    JS110 (XPO1) obtained IND approval from the NMPA.

    2021 Apr

    JS007 (CTLA-4) obtained IND approval from the NMPA.

    2021 Jun

    Toripalimab for the treatment of NPC obtained BLA acceptance and priority review from the FDA.

    2021 Oct

    VV116 (RdRp) was approval for COVID-19 treatment in Uzbekistan (not within the collaboration territory).

    JS109 (CD39) obtained IND approval from the NMPA.

    2021 Dec

    JS009 (CD112R) obtained IND approval from the FDA.

    Toripalimab for the treatment of small cell lung cancer (SCLC) was granted Orphan Drug Designation by the FDA.

    2022 Apr

    JS113 (EGFR 4th Gen) obtained IND approval from the NMPA.

    JS116 (KRAS) obtained IND approval from the NMPA.

    2022 Jun

    JS009 (CD112R) obtained IND approval from the NMPA.

    JS015 (DKK1) obtained IND approval from the NMPA.

    JS110 (XPO1) obtained IND approval from the FDA.

    2022 Aug

    Toripalimab for the treatment of NPC and ESCC obtained MAA acceptance from the EMA.

    2022 Dec

    Toripalimab for the treatment of NPC and ESCC obtained MAA acceptance from the MHRA.

    2023 Feb

    Our Leadership Team

    • Dr. Ning LIChief Executive Officer/General Manager

      Dr. Li is responsible for formulating business strategies and managing operation of the Junshi Biosciences.

      From 1997 to 2010, Dr. Li worked at US Food and Drug Administration (FDA) as a regulatory reviewer and held various positions from Oncology drug team reviewer, senior reviewer/expert reviewer, senior GCP medical reviewer to team leader, branch chief with increasing responsibilities. Before he joined Junshi Biosciences, Dr. Li was appointed as Vice President and Head of Region Asia and China Regulatory Affairs and Medical Policy in Sanofi. He has extensive experience and expertise in clinical research and medical product evaluation.

      Dr. Li obtained his bachelor’s degree in public health from Shanghai Medical College of Fudan University, the PRC in July 1984 and his master’s degree in medicine from Shanghai Medical College of Fudan University, the PRC in October 1987. He obtained his Ph.D. degree in preventive medicine from University of Iowa, the US in August 1994.

    • Mr. Cong LICo-Chief Executive Officer

      Mr. Li is responsible for commercialization and related work in Junshi Biosciences.

      Mr. Li has about two decades of experience working in pharmaceutical industry. Prior to joining Junshi Biosciences, Mr. Li was a lecturer on pathological anatomy of Shanghai Tiedao University School of Medicine. He also served as the sales director of the Shanghai branch of NOVO Nordisk (China) Pharmaceuticals. and held the positions of manager of East China Region, sales director, assistant to general manager and general manager at Tonghua Dongbao Pharmaceutical. Since June 2019, Mr. Li has been serving as director and general manager of Suzhou Landing Biopharmaceutical., and the responsible person of Shanghai branch office of Suzhou Landing Biopharmaceutical.

      Mr. Li obtained his bachelor’s degree in medical science from Shanghai Railway University Medical College in July 1986.

    • Dr. Hui FENGChief Operations Officer

      Dr. Feng is in charge of company operation. He is also the COO of TopAlliance, an executive director and legal representative of Junshi Biotechnology, and the legal representative, executive director and general manager of Suzhou Junmeng. He took part in the invention of certain registered patents and patents in application in relation to JS001, JS002 and JS003 for the company.

      Dr. Feng has over 10 years of industry experience in biotechnology and drug discovery. His experience spans across multiple areas of drug development including antibody discovery, protein engineering, and immuno-oncology. He worked at Albert Einstein College of Medicine and was a scientist in HumanZyme Inc. and MedImmune, Inc. (a subsidiary of AstraZeneca).

      Dr. Feng obtained his bachelor’s degree in biological sciences and technology from Tsinghua University, the PRC in July 1997 and his Ph.D. degree in molecular pharmacology from Albert Einstein College of Medicine, the US in September 2003. Dr. Feng has published a number of academic articles and is an inventor of a number of patents.

    • Mr. Zhuobing ZHANGDeputy General Manager

      Mr. Zhang was one of the founders of Junshi Biosciences when it was established. Since October 2013, Mr. Zhang has been the legal representative, executive director and general manager of Suzhou Union Biopharm.

      Mr. Zhang has over 20 years of experience in the pharmaceutical industry. Prior to joining Junshi Biosciences, he served as a scientific researcher of Viron Therapeutics Inc., Canada, and deputy director in Institute of Biopharmaceuticals of Nanjing Simcere Pharmaceutical Research Institute.

      Mr. Zhang obtained his master’s degree in biochemistry from Tsinghua University, PRC in July 1995. He was awarded the first prize of the Shandong district award for invention in 2005.

    • Dr. Sheng YAOSenior Vice President

      Dr. Yao is CEO and director of TopAlliance. He took part in the invention of certain registered patents and patents in application in relation to JS002 and JS003 for the company.

      Prior to joining Junshi Biosciences, Dr. Yao worked as research fellow at the Johns Hopkins University School of Medicine in the Department of Dermatology, associate research scientist in the Human Translational Immunology Department at Yale University, and senior scientist at Amplimmune Inc., a subsidiary of AstraZeneca, where he was responsible for the tumor immunology and anti-autoimmune diseases antibody project.

      Dr. Yao obtained his bachelor’s degree in biotechnology from School of Life Sciences of Peking University, the PRC in June 1998 and his Ph.D. degree in molecular genetics from Albert Einstein College of Medicine, the US in January 2003. Dr. Yao has a number of articles published in journals including Nature Communications, Science Advances, Immunity, Jem, Blood and JI. Dr. Yao is also an inventor of six registered patents or patents in application.

    • Dr. Jianjun ZOU, M.D, Ph.DDeputy General Manager Global Research and Development President

      Dr. Zou is responsible for the global research and development work in Junshi Bioscience.

      Dr. Zou has nearly 30 years of experience in clinical treatment of tumor, R&D of anti-tumor agents and clinical development of novel drugs. She had been working in the level 3 A hospital as a medical oncologist for 10 years from 1995 – 2005. Then she joined Bayer Healthcare pharmaceutical company and lead the clinical development programs of Sorafenib in China as the clinical trial physician, head of oncology therapeutic team in Bayer China. Then she moved to NJ, USA and worked as the global medical lead of Xofigo in the global medical affairs team in BayerhealtherCare Headquarter. In 2012, she joined Celgene and worked as the director, head of the medical department, China. Prior to joining Junshi Biosciences, she was the Vice President and chief medical officer(CMO) of JIANGSU HENGRUI MEDICINE, CO. LTD.

      Dr. Zou was trained by medical oncology in China and got her medical doctor degree in the Naval Medical University.

    • Dr. Gang WANGSenior Vice President of Industry Affairs Chief Quality Officer

      Dr. Wang is responsible for manufacturing quality and related work in Junshi Biosciences.

      He has been working in pharmaceutical industry for more than 30 years, with over 20 year experience in CGMP of biologics, and the review, manufacturing, pre-approval inspection, CGMP compliance inspection and supervision of biological products including cellular and gene therapy.

      Prior to joining Junshi Biosciences, Dr. Wang was Vice President for Quality (Shanghai) at WuXi Biologics (WuXi). Before that, he was Chief Scientist for Compliance and Inspection at Center for Drug Evaluation (CDE), CFDA, Assistant Country Director at the US FDA’s China Office in the US Embassy, etc.

      Dr. Wang received his bachelor’s degree in biochemistry from Nanjing University and Ph.D. in pharmacology and toxicology from Dartmouth Medical School in the US in 1995.

    • Dr. Patricia KEEGANChief Medical Officer

      Dr. Keegan is responsible for the strategy, direction and execution of the company’s clinical development plans.

      Dr. Keegan has over three decades of experience as a board-certified medical oncologist, clinical researcher, and regulatory authority at FDA. Prior to joining TopAlliance, Dr. Keegan served at FDA for 30 years, latest as Acting Associate Director of Medical Policy Oncology Center for Excellence (OCE), Office of the commissioner; 16 years as Division Director of Oncology Products; 4 years as Deputy Director Division of Clinical Trial Design and Analysis; 8 years as Chief and Medical officer at Oncology Branch. Prior to FDA, Dr. Keegan was Clinical Assistance Professor and medical oncologist at University of North Carolina at Chapel Hill.

      Dr. Keegan received her Bachelor of Science in Biology from University of Illinois Champaign-Urbana. She earned her medical degree from Loyola University Stritch School of Medicine. Dr. Keegan completed her residency in internal medicine at the Loyola University Medical Center, Maywood, Illinois, and her fellowship in medical oncology at Roswell Park Memorial Institute, Buffalo, New York.

    Globalization

    In China, For Global

    Starting from its global headquarters in Shanghai, Junshi Biosciences has established four R&D centers in Shanghai, Suzhou, San Francisco and Maryland, and two monoclonal antibody production bases in Wujiang, Suzhou and Lingang, Shanghai.

    map

    Headquarters / Shanghai Lingang Production Base

    • Establishment of stable cell line
    • Process optimization
    • cGMP standard
    • Establishment and maintenance of global quality system
    • Manufacturing of investigational products
    Shanghai

    Guangzhou

    Suzhou Innovation Center

    • Functional validation and process development of pipeline projects

    Suzhou Wujiang Production Base

    • Establishment of stable cell line
    • Process optimization
    • GMP standard production
    • Establishment and maintenance of global quality system
    • Investigational products and commercial manufacturing
    Suzhou

    Beijing

    Maryland Innovation Center

    • Human transmembrane receptor protein array and eukaryotic cell-based functional assay platform
    • Novel drug target screening
    • Evaluation and selection of antibody candidates
    • US clinical trials management
    Maryland

    San Francisco Innovation Center

    • Automated high-efficiency screening platform for antibody selection and functional assays
    • High-throughout antibody screening
    • Antibody humanization, selection and optimization
    San Francisco
    Top